I
iBio, Inc.
IBIOCIK 0001420720NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30
Period
FY 2025
Revenue
$400.0K
Net Income
$-18.38M
Total Assets
$23.18M
Equity
$14.88M
Shares Out
34.54M
Op. Cash Flow
$-15.30M
Business
iBio, Inc. is a preclinical biotechnology company that leverages artificial intelligence and machine learning to discover and design precision antibodies against hard-to-drug targets in obesity and cardiometabolic disease. It offers an AI Drug Discovery Platform and related discovery services, proprietary technologies (Epitope Steering, StableHu, EngageTx, ShieldTx) and a pipeline of antibody therapeutic candidates, including IBIO-600 and IBIO-610. Its operations encompass internal discovery, optimization and preclinical development and partnered programs with collaborators such as AstralBio and RubrYc. iBio conducts R&D primarily in the United States and engages partners and collaborators to advance and potentially commercialize programs globally.
Summary from filing dated 2025-09-05
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue | 400,000 | 225,000 | 0 | — | — | |
| Research and development | 8 | 5 | 10 | 10 | 10 | |
| General and administrative | 11 | 12 | 19 | 22 | 22 | |
| Total operating expenses | 19 | 17 | 29 | 32 | 32 | |
| Operating loss | −19 | −17 | −29 | −30 | −31 | |
| Interest expense | −212,000 | −172,000 | −83,000 | — | — | |
| Interest income | 437,000 | 363,000 | 213,000 | 177,000 | 140,000 | |
| Gain on sale of intellectual property | — | 1 | — | — | — | |
| Total other income | 225,000 | 1 | 32,000 | 184,000 | 8 | |
| Net loss from continuing operations | −18 | −15 | −29 | −30 | — | |
| Loss from discontinued operations | — | −9 | −36 | −21 | — | |
| Net loss | −18 | −25 | −65 | −50 | −23 | |
| Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations | −1.75 | −4.03 | −47.88 | −3.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations | −1.75 | −4.03 | −47.88 | −3.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations | — | −2.47 | −58.31 | −2.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations | — | −2.47 | −58.31 | −2.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - basic - total | −1.75 | −6.5 | −106.19 | −5.78 | −3 | |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - total | −1.75 | −6.5 | −106.19 | −5.78 | −3 | |
| Weighted-average common shares outstanding - basic | 10 | 4 | 612,000 | 9 | 8 | |
| Weighted-average common shares outstanding - diluted | 10 | 4 | 612,000 | 9 | 8 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | 14 | 4 | 23 | — | |
| Subscription receivable | 105,000 | — | 204,000 | — | — | |
| Promissory note receivable and accrued interest | — | 713,000 | — | — | — | |
| Prepaid expenses and other current assets | 1 | 749,000 | 664,000 | 2 | — | |
| Total Current Assets | 10 | 16 | 26 | 45 | — | |
| Restricted cash | 210,000 | 215,000 | 253,000 | 6 | — | |
| Promissory note receivable | 1 | 1 | 2 | — | — | |
| Finance lease right-of-use assets, net of accumulated amortization | 68,000 | 339,000 | 610,000 | 74,000 | — | |
| Operating lease right-of-use asset | 2 | 2 | 3 | 3 | 2 | |
| Fixed assets, net of accumulated depreciation | 3 | 4 | 4 | 1 | — | |
| Intangible assets, net of accumulated amortization | 7 | 5 | 5 | 5 | — | |
| Security deposits | 26,000 | 26,000 | 50,000 | 29,000 | — | |
| Total Assets | 23 | 29 | 41 | 99 | — | |
| Accounts payable | 2 | 358,000 | 2 | 4 | — | |
| Accrued expenses | 1 | 2 | 5 | 4 | — | |
| Finance lease obligations - current portion | 53,000 | 299,000 | 272,000 | 46,000 | — | |
| Operating lease obligation - current portion | 490,000 | 436,000 | 389,000 | 91,000 | — | |
| Equipment financing payable - current portion | 64,000 | 178,000 | 160,000 | — | — | |
| Term promissory note - current portion | 766,000 | 218,000 | 13 | 22 | — | |
| Insurance premium financing payable | — | 123,000 | — | — | — | |
| Contract liabilities | 1 | 200,000 | 0 | 100,000 | — | |
| Total Current Liabilities | 6 | 4 | 22 | 30 | — | |
| Finance lease obligations - net of current portion | — | 53,000 | 351,000 | 30,000 | — | |
| Operating lease obligation - net of current portion | 2 | 3 | 3 | 4 | — | |
| Equipment financing payable - net of current portion | — | 63,000 | 241,000 | — | — | |
| Term promissory note - net of current portion | — | 766,000 | — | — | — | |
| Total Liabilities | 8 | 7 | 26 | 36 | — | |
| Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2025 and June 30, 2024; 19,349,201 and 8,623,676 shares issued and outstanding as of June 30, 2025 and June 30, 20243, respectively | 19,000 | 9,000 | 1,000 | 9,000 | — | |
| Additional paid-in capital | 347 | 335 | 304 | 288 | — | |
| Accumulated deficit | −332 | −314 | −289 | −224 | — | |
| Total Stockholders' Equity | 15 | 21 | 15 | 63 | — | |
| Total Liabilities and Stockholders' Equity | 23 | 29 | 41 | 99 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Consolidated net loss | −18 | −25 | — | — | — | |
| Share-based compensation | 2 | 2 | 4 | 4 | 2 | |
| Amortization of intangible assets | 20,000 | 20,000 | 126,000 | 401,000 | 291,000 | |
| Amortization of finance lease right-of-use assets | 271,000 | 271,000 | 224,000 | 599,000 | 2 | |
| Amortization of operating lease right-of-use assets | 351,000 | 321,000 | 356,000 | 516,000 | — | |
| Depreciation of fixed assets | 484,000 | 638,000 | 674,000 | 2 | 472,000 | |
| Gain on sale of fixed assets | — | 5 | −773,000 | — | — | |
| Gain on extinguishment of debt | — | −808,000 | — | — | — | |
| Accrued interest receivable on promissory note receivable | −62,000 | −88,000 | −75,000 | — | — | |
| Amortization of deferred financing costs | — | 120,000 | 242,000 | — | — | |
| Impairment of fixed assets | — | 3 | — | — | — | |
| Prepaid expenses and other current assets | −408,000 | 214,000 | 885,000 | 307,000 | −2 | |
| Security deposit | — | 24,000 | — | — | — | |
| Accounts payable | 2 | −1 | −625,000 | 1 | 48,000 | |
| Accrued expenses | −758,000 | −2 | 145,000 | 1 | 2 | |
| Operating lease obligations | −436,000 | −389,000 | −101,000 | −15,000 | — | |
| Contract liabilities | 250,000 | 200,000 | −100,000 | 7,000 | −1 | |
| Net cash used in operating activities | −15 | −19 | −30 | −37 | −30 | |
| Payment received for interest and principal on promissory note receivable | 758,000 | — | — | — | — | |
| Sale proceeds for intangible assets | — | 1 | — | — | — | |
| Purchase of fixed assets | −16,000 | −210,000 | −6 | −7 | −5 | |
| Sales proceeds for fixed assets | — | 116,000 | 3 | — | — | |
| Net cash provided by investing activities | 742,000 | 906,000 | 7 | −5 | −26 | |
| Proceeds from sales of common stock | 4 | 26 | 11 | — | — | |
| Proceeds from Warrant Inducement | 6 | — | — | — | — | |
| Payments made for costs to acquire capital | −294,000 | −88,000 | — | — | — | |
| Payments for fractional shares after reverse stock split | — | −7,000 | — | — | — | |
| Proceeds from the exercise of stock options | 131,000 | — | 0 | 77,000 | 54,000 | |
| Subscription receivable | — | 204,000 | — | — | — | |
| Payment of equipment financing loan | −178,000 | −160,000 | −99,000 | — | — | |
| Proceeds from term promissory note | — | 895,000 | — | — | — | |
| Payment of term promissory note | −218,000 | −88,000 | −9 | — | — | |
| Payment of term note payable | — | −2 | −9 | — | — | |
| Payment of finance lease obligation | −299,000 | −272,000 | −208,000 | −6 | −331,000 | |
| Net cash provided by financing activities | 9 | 24 | 2 | −6 | 79 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −6 | 7 | −21 | −49 | 22 | |
| Indefinite-lived intangible asset addition | 2 | — | — | — | — | |
| Shares issued to AstralBio for license fee | −750,000 | — | — | — | — | |
| Credit provided by AstralBio | −750,000 | — | — | — | — | |
| Insurance premium financing | — | 669,000 | — | — | — | |
| Subscription receivable | 105,000 | — | — | — | — | |
| Costs to raise capital paid directly from gross proceeds | 81,000 | 1 | — | — | — | |
| Costs to raise capital included in accrued expenses | 75,000 | 308,000 | — | — | — | |
| Issuance of warrant for term note payable obligation | — | 4 | — | — | — | |
| Reserves related to term promissory note included in prepaid expenses | — | 109,000 | — | — | — | |
| Costs related to tern promissory note paid directly from gross proceeds | — | 68,000 | — | — | — | |
| Cash paid during the period for interest | 212,000 | 749,000 | 687,000 | 1 | 2 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro